CoChat

Potential therapeutic target for aging and age-related neurodegenerative diseases: the role of acid sphingomyelinase

Open access
Park, Min Hee, Jin, Hee Kyung, Bae, Jae-sung · 2020 · Experimental & Molecular Medicine

The DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.

Abstract

Aging, which is associated with age-related changes in physiological processes, is the most significant risk factor for the development and progression of neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Accumulating evidence has indicated that sphingolipids are significant regulators that are associated with pathogenesis in aging and several age-related neurodegenerative diseases. In particular, abnormal levels of acid sphingomyelinase (ASM), one of the significant sphingolipid-metabolizing enzymes, have been found in the blood and some tissues under various neuropathological conditions. Moreover, recent studies have reported the importance of ASM as a critical mediator that contributes to pathologies in aging and age-related neurodegenerative diseases. In this review, we describe the pathophysiological processes that are regulated by ASM, focusing on the age-related neurodegenerative environment. Furthermore, we discuss novel insights into how new therapeutics targeting ASM may potentially lead to effective strategies to combat aging and age-related neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s12276-020-0399-8

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 ASM-mediated physiological dysfunction in aging. ASM activity increases with aging. In the aged brain, ASM levels increase in ECs of the BBB. EC-derived ASM induces BBB hyperpermeability by excessive caveolae transcytosis via PP1-mediated ERM dephosphorylation. This results in extravasation of blood-derived molecules into the brain parenchyma, leading to neuronal cell death and memory impairment. Plasma ASM levels also increase with aging, and ASM is likely to promote inflammation by causing immune cell dysfunction, such as macrophage activation and dysregulation of T cell differentiation. In aged hearts, increased ASM in muscle cells induces ceramide production. Ceramide mediates a decrease in mitochondrial cardiolipin, and this reduction contributes to mitochondrial dysfunction and cardiac impairment.
Fig. 1 ASM-mediated physiological dysfunction in aging. ASM activity increases with aging. In the aged brain, ASM levels increase in ECs of the BBB. EC-derived ASM induces BBB hyperpermeability by excessive caveolae transcytosis via PP1-mediated ERM dephosphorylation. This results in extravasation of blood-derived molecules into the brain parenchyma, leading to neuronal cell death and memory impairment. Plasma ASM levels also increase with aging, and ASM is likely to promote inflammation by causing immune cell dysfunction, such as macrophage activation and dysregulation of T cell differentiation. In aged hearts, increased ASM in muscle cells induces ceramide production. Ceramide mediates a decrease in mitochondrial cardiolipin, and this reduction contributes to mitochondrial dysfunction and cardiac impairment.CC BY · PubMed Central
Fig. 2 Schematic summary of ASM-mediated pathophysiology and therapeutic effects of ASM inhibition in AD. In AD, ASM is increased in neurons by environmental or cellular stress. Intracellular and secreted ASM can be taken up into the lysosome via M6PR. Excessively increased lysosomal ASM affects lysosomal disruption, and intracellular ASM decreases lysosome biogenesis. This lysosomal disruption by ASM inhibits autophagic protein degradation and further leads to the accumulation of autophagosomes and abnormal proteins, such as Aβ and cytotoxic proteins. Eventually, autophagic flux decreases and induces Aβ deposition and memory impairment in AD. ASM inhibition by functional inhibitors such as amitriptyline blocks AD progression by ameliorating the autophagic process.
Fig. 2 Schematic summary of ASM-mediated pathophysiology and therapeutic effects of ASM inhibition in AD. In AD, ASM is increased in neurons by environmental or cellular stress. Intracellular and secreted ASM can be taken up into the lysosome via M6PR. Excessively increased lysosomal ASM affects lysosomal disruption, and intracellular ASM decreases lysosome biogenesis. This lysosomal disruption by ASM inhibits autophagic protein degradation and further leads to the accumulation of autophagosomes and abnormal proteins, such as Aβ and cytotoxic proteins. Eventually, autophagic flux decreases and induces Aβ deposition and memory impairment in AD. ASM inhibition by functional inhibitors such as amitriptyline blocks AD progression by ameliorating the autophagic process.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 103 references

Cited by

See all 65

Metadata

Authors
Park, M. H., Jin, H. K., & Bae, J.-S.
Affiliations
Kyungpook National University (KR)
Corresponding author
Bae, Jae-sung
Venue
Experimental & Molecular Medicine
Published
2020-03
Volume
52
Issue
3
Pages
380-389
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W3011605603
Cited by
59
References
105
Citations by year
2026: 5 · 2025: 7 · 2024: 12 · 2023: 9 · 2022: 10 · 2021: 15 · 2020: 1
FWCI
0.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Experimental & Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Korea Health Industry Development Institute
  • Ministry of Science and ICT, South Korea (2017R1A4A1015652)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
acid sphingomyelinase, aging, age-related neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, sphingolipids, sphingolipid metabolism, therapeutic target, enzyme inhibition
MeSH terms
Aging, Animals, Humans, Sphingomyelin Phosphodiesterase, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential therapeutic target for aging and age-related neurodegenerative diseases: the role of acid sphingomyelinase. https://app.cochat.ai/papers/10.1038/s12276-020-0399-8
The paper
Park, M. H., Jin, H. K., & Bae, J.-S. (2020). Potential therapeutic target for aging and age-related neurodegenerative diseases: the role of acid sphingomyelinase. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-020-0399-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.